Dermatology News

The FDA has approved Abrilada as the second interchangeable biosimilar to adalimumab, according to a press release from Pfizer.

Although the current net price of adalimumab biosimilar Amjevita is lower for commercial health plans than that of the originator, it is nonetheless “more than double” what Humira cost at launch in 2003, according to a research letter.

A 5-day-old female is transferred from another hospital due to irritability and a worsening pustular rash. The mother’s pregnancy, labor and delivery was complicated by a group B strep-positive culture and vaginal candidiasis.

In this edition, CDC issues a health advisory concerning flesh-eating bacterium, staging for melanoma does not represent accurate recurrence and mortality and more.

SAN DIEGO — Patient age and disease-related factors may be driving safety signals in medications used to treat rheumatoid arthritis and psoriatic disease, according to a speaker at the 2023 Congress of Clinical Rheumatology West.

Women who wear hijab are among the highest risk for developing traction alopecia, yet they are likely underrepresented in alopecia studies, according to a letter in Journal of the American Academy of Dermatology.

On Sept. 1, the CDC issued a health advisory concerning an increased rate of infections in the United States of a flesh-eating bacterium called Vibrio vulnificus.

Patient-reported outcomes in individuals with psoriatic arthritis receiving either ustekinumab or TNF inhibitors were “generally comparable” after 3 years of follow-up, according to data published in Arthritis Research & Therapy.

Patients with rheumatoid arthritis who receive TNF inhibitors are more likely to develop psoriasis vs. those treated with methotrexate, according to an analysis of more than 880,000 post-marketing reports published in Scientific Reports.

Following the release of the “Barbie” movie in July 2023, a new cosmetic trend called “Barbie Botox” has taken social media by storm.